antibody-engineering
(13)
Merida Biosciences
Merida Biosciences is a Cambridge, Massachusetts biotechnology company developing a new class of engineered Fc biotherapeutics that selectively bind and eliminate the disease-causing antibodies behind autoimmune and allergic diseases, while sparing the protective antibodies the immune system needs. Launched publicly in April 2025 with a $121 million Series A, the company aims to treat conditions such as Graves' disease, IgE-mediated allergy and primary membranous nephropathy by clearing pathogenic antibodies and suppressing the B cells that make them - without the broad immunosuppression that limits many existing therapies.
Jason Gardner
Jason Gardner is the CEO of Ampersand Biomedicines and a CEO-Partner at Flagship Pioneering, where he leads a Boston-area biotech programming biologic medicines that act only at the site of disease. A Cambridge- and Oxford-trained scientist turned operator, he previously co-founded and ran Magenta Therapeutics through its IPO and spent years building GSK's Regenerative Medicine Unit. He is betting that the next generation of drugs will not just be potent but precise - going exactly where they are needed and nowhere else.
EpiBiologics
EpiBiologics is a San Mateo biotech building bispecific antibodies that grab disease-driving proteins on the outside of cells and drag them into the trash. Its EpiTAC platform - spun out of Jim Wells' lab at UCSF - taps a library of more than 270 internalizing receptors so degradation happens in the right tissue and nowhere else. With $280M raised across Seed, Series A and a 2026 Series B led by GV and Johnson & Johnson, the company has pushed its lead EGFR degrader, EPI-326, into a Phase 1 trial for lung and head-and-neck cancers.
Bonum Therapeutics
Bonum Therapeutics is a Seattle biotechnology company building conditionally active biologics - drugs that switch on only where they are needed and switch off everywhere else. Spun out of Good Therapeutics after Roche's $250M acquisition in 2022, Bonum kept the platform blueprint and its founding team, then raised a $93M Series A to extend the approach. Its patented dual-binding antibody (DBA) technology uses a single domain that binds either an effector cytokine or a marker protein, but only one at a time, creating fully reversible medicines aimed at cancer, autoimmunity, metabolic disease and pain.
Alexey Lugovskoy
Alexey 'Alex' Lugovskoy is the co-founder and CEO of Diagonal Therapeutics, a Watertown/Cambridge, Massachusetts biotech building 'clustering' antibodies that switch cellular signaling back on rather than block it. A Harvard-trained biophysicist who left physics after deciding green leaves were more interesting than tau neutrinos, he spent two decades in antibody R&D at Biogen, Merrimack, Morphic, and Dragonfly before launching Diagonal in 2022. He has co-invented an FDA-approved cancer drug, authored more than 100 patents and papers, and edits the antibody journal mAbs. In January 2026 Diagonal closed an oversubscribed $125M Series B co-led by Sanofi Ventures and Janus Henderson to push its lead program, DIAG723, into human trials for hereditary hemorrhagic telangiectasia.
Salubris Biotherapeutics
Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company in Gaithersburg, Maryland that engineers complex biologics for diseases with few good options - chiefly heart failure and cancer. Founded in 2016 as the US arm of China's Shenzhen Salubris Pharmaceuticals, its lead candidate JK07 is an antibody-fusion protein designed to harness the regenerative NRG-1/ErbB4 pathway in failing hearts while dialing out the side effects, and its oncology programs JK08 and JK06 pursue solid tumors through immune engagement and a 5T4-targeted biparatopic antibody-drug conjugate.
Tamarind Bio
Tamarind Bio is a San Francisco software company building cloud infrastructure that lets bench scientists run 250+ AI and physics-based models for drug discovery - tools like AlphaFold, RFdiffusion, ProteinMPNN and GROMACS - through a no-code web interface and API, without managing GPUs, data pipelines or DevOps. Founded in 2023 by Stanford computer scientist Deniz Kavi and Sherry Liu, the company serves over 10,000 scientists, including 8 of the top 20 pharmaceutical companies, and raised a $13.6M Series A in February 2026.
Triveni Bio
Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.
Ampersand Biomedicines
Ampersand Biomedicines is a Boston-area biotech founded by Flagship Pioneering that builds programmable biologic medicines designed to act only where disease lives. Its computational Address, Navigate, Determine (AND) Platform maps the body for ideal localization targets and designs AND-Body Therapeutics that anchor at a disease site and conditionally switch on biology there, aiming to widen the therapeutic window and cut the off-tissue side effects that limit conventional drugs.
Crossbow Therapeutics, Inc.
Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company building a new class of cancer immunotherapies. Its T-Bolt platform engineers TCR-mimetic antibodies - T-cell engagers that recognize tiny peptide fragments displayed on a cancer cell's surface (peptide-HLA complexes), opening up intracellular proteins that conventional antibodies cannot reach. The lead program, CBX-250, is a first-in-class T-cell engager in a Phase 1 trial for relapsed or refractory myeloid malignancies. Backed by more than $157M in venture funding, Crossbow aims to expand the universe of targetable cancer antigens.
Abdera Therapeutics
Abdera Therapeutics is a precision oncology biotech engineering antibody-based radiopharmaceuticals that deliver therapeutic radioisotopes directly to tumor cells while sparing healthy tissue. Built around its proprietary ROVEr platform, the company is advancing ABD-147 in Phase 1 trials for small cell lung cancer and large cell neuroendocrine carcinoma, with a second program, ABD-320, on deck.
Jennifer Cygan
Jennifer Cygan is a seasoned biotech executive and Chief Business Officer at EpiBiologics, where she helps advance a pipeline of novel bispecific antibodies designed to selectively degrade extracellular protein targets in oncology and immunology. With a Ph.D. from Harvard and over two decades of business leadership in biotechnology, she has been a pivotal force at Genentech, Calico Life Sciences (managing a $2.5B AbbVie alliance), and has co-founded and served as CBO for multiple emerging biotech companies including Broadwing Bio, Eikon Therapeutics, GenEdit, and Plexium. Her career sits at the intersection of science and strategy - translating cutting-edge biology into deals, partnerships, and companies that matter.
Roy Maute
Roy Maute is co-founder and CEO of Pheast Therapeutics, a clinical-stage biotech in Redwood City, CA, developing macrophage-targeted cancer immunotherapies. Trained at UC Berkeley, Columbia (PhD, Genetics), and Stanford (postdoc under Irving Weissman), Maute has built a career at the intersection of innate immunology and drug development. Before Pheast, he co-founded Ab Initio Biotherapeutics (acquired by Ligand in 2019) and led translational research at Forty Seven Inc. ahead of its $4.9B acquisition by Gilead in 2020. At Pheast, he is advancing PHST001, a novel anti-CD24 antibody that teaches macrophages to eat cancer cells, currently in Phase 1 clinical trials with FDA Fast Track Designation for ovarian cancer.